IFNB1 and myeloid sarcoma: We profiled B cell and non-B-cell gene expression and protein signatures from MS peripheral blood mononuclear cells (PBMC) and serum before and after ocrelizumab treatment compared to therapy-naïve and IFN-β-treated MS patients.